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Background: Cigarette smoking is a common and lethal worldwide habit, with considerable mortality stemming
from its deleterious effects on heart function. While current theories posit altered blood lipids and fibrinogen
metabolism as likely mediators, none have explored the role of the sphingolipid ceramide in exacerbating heart
function with smoke exposure. Ceramide production is a consequence of cigarette smoke in the lung, and
considering ceramide’s harmful effects on mitochondrial function, we sought to elucidate the role of ceramide in
mediating smoke-induced altered heart mitochondrial respiration.
Methods: Lung cells (A549) were exposed to cigarette smoke extract (CSE) and heart cells (H9C2) were exposed to
the lung-cell conditioned medium. Adult male mice were exposed sidestream cigarette smoke for 8 wk with dietary
intervention and ceramide inhibition. Ceramides and heart cell or myocardial mitochondrial respiration were
determined.
Results: Lung cell cultures revealed a robust response to cigarette smoke extract in both production and
secretion of ceramides. Heart cells incubated with lung-cell conditioned medium revealed a pronounced inhibition of
myocardial mitochondrial respiration, though this effect was mitigated with ceramide inhibition via myriocin. In vivo,
heart ceramides increased roughly 600% in adult mice with long-term sidestream cigarette smoke exposure. This
resulted in a significant ceramide-dependent reduction in left myocardial mitochondrial respiration, as heart
mitochondria from the mice exposed to both smoke and myriocin injections respired normally.
Conclusions: These results suggest ceramide to be an important mediator of altered myocardial mitochondrial
function with cigarette smoke exposure. Thus, anti-ceramide therapies might be considered in the future to
protect heart mitochondrial function with smoke exposure.Background
Cigarette smoke exposure is the leading cause of pre-
ventable deaths worldwide [1] and is among the top ten
contributors to the worldwide health burden [2]. Despite
concerted social efforts to reduce smoking prevalence,
current trends suggest the number of smokers will in-
crease worldwide [3,4]. Moreover, cigarette smoke is a
common inhaled toxin—almost half of the U.S. population
is regularly exposed to cigarette smoke [5,6] and appro-
ximately 20% of young children live with someone who* Correspondence: benjamin_bikman@byu.edu
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unless otherwise stated.smokes in the home [7]. Much of smoking’s health burden
stems from the increased risk of chronic diseases like can-
cer, emphysema, and cardiovascular disease [8,9], includ-
ing cardiomyopathy—a deterioration of heart muscle.
Cardiomyocytes are highly oxidative cells with a tre-
mendous reliance on mitochondrial capacity [10], and
altered mitochondrial function can lead to heart failure
[11-13], a common consequence of cardiomyopathy. Con-
sidering the importance of healthy mitochondrial function
in cardiomyocyte homeostasis, a valuable area of study
is to elucidate the factors that mediate altered heart
mitochondrial physiology and its effects with cigarette
smoke exposure. Previous studies have observed that
cigarette smoke exposure inhibits mitochondrial respiratoryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mediating mechanism has yet to be identified.
Cigarette smoke has long been known to robustly activate
inflammatory pathways in the lung [16], which increases
ceramide biosynthesis [17,18]. Importantly, ceramides are
known to disrupt mitochondrial structure and function
[19,20], possibly increasing risk of cardiomyopathy [21].
Thus, the purpose of these studies was to determine
whether the sphingolipid ceramide mediates cardiomyocyte
mitochondrial disruption with cigarette smoke exposure.
Considering the lung’s apposition with the environment,
the lung is a logical site of external pathogen-induced
stress, a product of which is ceramide biosynthesis [17].
Moreover, given the heart’s location relative to pulmonary




Cigarette smoke extract (CSE) was generated as previ-
ously described with slight modifications [22]. Briefly,
one 2RF4 research cigarette (University of Kentucky,
Lexington, KY) was continuously smoked by connecting
the filtered end of the cigarette to a vacuum pump, pulling
the particles into 5 ml of DMEM/F12 and the resulting
medium was defined as 100% CSE. The total particulate
matter content of 2RF4 cigarettes is 11.7 mg/cigarette, tar
is 9.7 mg/cigarette, and nicotine is 0.85 mg/cigarette. Dilu-
tions were made using DMEM/F12 + 10% FBS. Human
type II–like pulmonary adenocarcinoma cells (A-549;
passage 10-15) were maintained in DMEM/F12 supple-
mented with 10% FBS (Invitrogen) and antibiotics. Cells
were split into 6-well dishes and grown to 80% conflu-
ence. H9C2 cardiomyocytes were maintained in DMEM
+10% FBS. For differentiation into myotubes, cells were
grown to confluency and the medium was replaced with
DMEM +10% horse serum (Invitrogen, Grand Island,
NY). Myotubes were used for experiments on day 3 of
differentiation. A-549 cultures were exposed to media
supplemented with 10% CSE or media alone for 4 h,
after which the medium was transferred to differentiated
H9C2 cardiomyocytes (termed “conditioned medium”) for
12 h. Where indicated, cells were treated with myriocin
(10 μM, Sigma, M1177), a known and widely used inhibi-
tor of ceramide biosynthesis. Muscle cells were harvested
for RNA, protein, and lipid isolation following treatments.
Cell survival during treatments was confirmed by trypan
blue exclusion.
Animals
Male C57Bl6 mice were housed in a conventional animal
house and maintained on a 12-hour light–dark cycle.
Two animal studies were conducted. In the first study,
animals received standard diet chow (Harlan Teklad8604) and water ad libitum. At 12 wk of age, animals
were randomly divided into room air and cigarette
smoke (CS)-exposed groups. Mice were placed in soft
restraints and connected to the exposure tower of a
nose-only exposure system (InExpose System, Scireq,
Canada). Animals were nasally exposed to sidestream CS
generated by research cigarettes where a computer-
controlled puff was generated every minute, leading to
10 min of CS exposure followed by 10 min of fresh air,
repeated once. The CS-exposed group inhaled CS from
two cigarettes per day for one week, at which point the
dosage was increased to two cigarettes twice daily.
Control animals were similarly handled and restrained in
fresh air for the same duration. For the second study,
12-wk-old mice were separated into one of eight treat-
ment groups for eight weeks. Each of the following
groups were duplicated to have one group receive
vehicle or myriocin injections (0.3 mg/kg) every other
day for a total of eight groups: 1) control – standard diet
chow, no smoke; 2) cigarette smoke exposure (two ciga-
rettes, twice daily) with standard diet chow; 3) high-fat,
high-sugar diet (Harlan Teklad 45F30S); 4) high-fat,
high-sugar diet with cigarette smoke exposure. Tissues
were harvested at the conclusion of the study period.
Studies were conducted in accordance with the princi-
ples and procedures outlined in the National Institutes
of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal
Care and Use Committee (IACUC) at Brigham Young
University.
Lipid analysis
For isolation of lipids, cell pellets or tissue were sus-
pended in 900 μl ice-cold chloroform/methanol (1:2)
and incubated for 15 minutes on ice, then briefly
vortexed. Separation of aqueous and organic phases
required addition of 400 μl of ice-cold water and 300 μl
of ice-cold chloroform. The organic phase was col-
lected into a fresh vial, and lipids were dried in a
vacuum centrifuge (Eppendorf Concentrator Plus).
Lipids were characterized and quantified using a shot-
gun lipidomics technique on a Thermo Scientific LTQ
Orbitrap XL mass spectrometer. Evaporated lipid sam-
ples were re-suspended in a 2:1 chloroform: methanol
Folch solution (200 μL). The re-suspended lipids were
then combined with a modified 2:1:1.25 chloroform:
methanol: isopropanol Bligh and Dyer solution (800 μL)
with 15 mM ammonium acetate acting as an ionizing
adduct. A 1.74 μM phosphatidylethanolamine, 1 μM C-17
ceramide, 1 μM tripalmitin internal standard cocktail
(1 μL) was spiked into each sample for mass calibration
and characterization data alignment. Samples were ana-
lyzed using a 2.5-minute mass-window scanning method
in positive-ion mode at a resolution of 100,000 (FWHM at
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data was also collected (PQD at relative intensity of 35)
and manually verified for each mass window to give
additional confidence to the correct identification of abun-
dant lipid species. Three technical replicate mass spec-
trometer runs were performed on each sample. Samples
were injected at 8 μL/min using a direct-inject electrospray
ionization (ESI) soft-ionization spray head from a Hamilton
GASTIGHT glass syringe. A nitrogen sheath gas spray flow
rate of 8 (arb. Units) was used for all runs. The spray
voltage and capillary temperature were maintained at
5.0 KV and 275°C respectively. Each technical replicate
was run in random order to reduce systematic bias.
Data were analyzed using in-house developed peak
summarization, recalibration, and lipid identification
software using lipid database information from the
LIPID Metabolites and Pathways Strategy (Lipid MAPS)
Lipidomics Gateway database [23]. To ensure high-
confidence identifications, an intensity threshold estimated
to be 5% above instrumental static signal was implemented.
Lipid identities were only assigned when significantly ob-
servable peaks were identified in at least two of the three
technical replicate runs. Non-zero lipid quantities were
averaged from the replicate runs. The lipid speciesFigure 1 Ceramide inhibits left ventricle mitochondrial respiration. A: Re
with addition of C2-ceramide during respiration protocol (20 μM; n = 4). B: Mi
(30 min) with continuous incubation with C2-ceramide (20 μM; n = 8). See Meidentified across different ionization states or with ad-
ducts were totaled together. Quantification was com-
pleted by normalizing total ion counts to the relative
abundance of the internal standard that was spiked into
each sample.
Cell and myocardium permeabilization
For cells, H9C2 cardiomyocytes were detached in culture
dishes with 0.05% trypsin-EDTA (Sigma) and growth
medium was added to the culture. Contents were trans-
ferred to a tube and centrifuged for 10 min at 1000 × g
at RT. After removal of supernatant, cells were lifted
in MiR05 [0.5 mM EGTA, 3 mM MgCl2, 60 mM K-
lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM
HEPES, 110 mM sucrose, and g/l BSA (Sigma; A3803)
adjusted to pH 7.1] plus 1 mg/ml digitonin and gently
rocked at RT for 5 min before centrifugation at 1000 × g
for 5 min. After discarding supernatant, cells were then
suspended in 2.2 ml warm MiR05 and transferred to
chambers in the O2K (Oroboros Instruments, Innsbruck,
Austria). Following respiration protocol (outlined below),
cells were removed from the chambers and used for
further analysis, including protein quantification. For
myocardial mitochondrial respiration, left ventricle wasspiration rates of mitochondria isolated from left ventricle myocardium
tochondrial respiration from permeabilized left ventricle myocardium
thods for more details on respiration protocol. *P <0.05.
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ately placed in ice-cold buffer X (60 mM K-MES,
35 mM KCl, 7.23 mM K2EGTA, 2.77 mM CaK2EGTA,
20 mM imidazole, 20 mM tuarine, 5.7 mM ATP,
15 mM PCr, 6.56 mM MgCl2-6H2O, pH 7.1) and
trimmed of connective tissue. Small fiber bundles were
prepared and gently separated along their longitudinal
axis under a surgical scope (Olympus, ST) to 1-2 mg.
Bundles were then transferred to a tube with chilled
buffer X and 50 μg/ml saponin and rocked at 4°C for
30 min, then washed in buffer Z (105 mM K-MES,
30 mM KCl, 10 mM KH2PO4, 5 mM MgCl2-6H2O,
0.5 mg/ml BSA, pH 7.1) at 4°C for at least 15 min. Sam-
ples were then blotted dry and weighed.
Mitochondrial isolation
To isolate mitochondria from left ventricle myocar-
dium, the whole heart was placed in isolation buffer
(300 mM sucrose, 10 mM Na-HEPES, 0.2 mM EDTA,
pH 7.2) and the left ventricle isolated. After finely min-
cing the sample, trypsin (Sigma T9935) was added for
two minutes before adding trypsin inhibitor (SigmaFigure 2 Lung cells make and secrete ceramide in response to cigare
PBS- or 10% cigarette smoke extract-containing medium without (CSE) o
(n = 6). B: Ceramides in culture medium of A549 cells following a 12-h tr
from whole blood of adult mice following 5 d of room air (CON) or side
vs. PBS.T9003). The sample was then transferred to a conical
tube and allowed to settle. After removal of supernatant,
samples were resuspended in isolation buffer with BSA
(Sigma A3803) and homogenized with Teflon pestle
before centrifugation (600 × g for 10 min at 4°C). Super-
natant was then transferred to a new tube and centrifuged
(8000 × g for 15 min at 4°C), then washed by gently adding
isolation buffer and rotating the tube. A portion of this
suspension is used for protein quantification. The pellet
was then resuspended with isolation buffer + BSA.
Mitochondrial respiration protocol
High-resolution O2 consumption was determined at
37°C in permeabilized cells and fiber bundles using the
Oroboros O2K Oxygraph with MiR05 respiration buf-
fer. Before addition of sample into respiration cham-
bers, a baseline respiration rate was determined. After
addition of sample, the chambers were hyperoxy-
genated to ~350 nmol/ml. Following this, respiration
was determined by all or parts of the following
substrate-uncoupler-inhibitor-titration (SUIT) protocol
[24]: electron flow through complex I was supported bytte smoke extract. A: Ceramide levels in A549 cells treated with
r CSE with myriocin (CSE + Myr), a ceramide inhibitor, for 12 h
eatment with PBS or CSE (n = 6). C. Ceramides were determined
stream cigarette smoke (CS) (P =0.069; n = 5). *P <0.05 for CSE
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termine basal oxygen consumption (GMB). Following
stabilization, ADP (2.5 mM) was added to determine
oxidative phosphorylation capacity (GMP). Succinate
was added (GMSP) for complex I + II electron flow into
the Q-junction. To determine full electron transport
system (F) capacity over oxidative phosphorylation,
the chemical uncoupler carbonyl cyanide 4-(trifluo-
romethoxy) phenylhydrazone (FCCP) was added (0.05 μM,
followed by 0.025 μM steps until maximal O2 flux was
reached). Complex II-supported ETS was then mea-
sured by inhibiting complex I with rotenone (Rot;
0.5 μM). Mitochondrial membrane integrity was tested
in all experiments by adding cytochrome c (10 μM;
GMcP). Lastly, residual oxygen consumption was mea-
sured by adding antimycin A (2.5 μM) to block com-
plex III action, effectively stopping any electron flow,
which provides a baseline rate of respiration. WhereFigure 3 Ceramide is necessary for decreased mitochondrial respirati
medium from CSE-treated lung cells. A: Ceramide levels in H9C2 cardiom
cells following incubation with normal growth medium (Con), Con with my
(n = 4). B: Mitochondrial respiration from H9C2 cardiomyocytes followin
details on respiration protocol. *P <0.05 for CSE vs. Con.indicated, C2-ceramide (Sigma A7191; 20 μM) was
added to respiration chambers.
Statistics
Data are presented as the mean ± SEM. Data were com-
pared by ANOVA with Tukey’s post-hoc analysis (Graph-
pad Prism; La Jolla, CA). Significance was set at p <0.05.
Results
Ceramide inhibits cardiomyocyte mitochondrial respiration
To determine the effects of ceramide on cardiac mito-
chondrial respiration, we utilized two models. First, mito-
chondria were isolated from left ventricle myocardium.
During the course of the respiration protocol in the
isolated mitochondria, C2-ceramide was added to one
oxygraph chamber. The addition of ceramide (+C2) elicited
a rapid and significant reduction in mitochondrial
respiration that was sustained through maximal respirationon in myocardial cells following treatment with conditioned
yocytes treated with conditioned medium from A549 alveolar type 2
riocin (Myr), cigarette smoke extract (CSE), and CSE with Myr (CSE +Myr)
g treatment in identical conditions (n = 5). See Methods for more
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second model was the use of permeabilized intact left
ventricle myocardium. One sample was incubated with C2-
ceramide throughout the length of the protocol, which elic-
ited a sustained reduction in mitochondrial respiration
throughout the entire protocol (Figure 1B).Cigarette smoke extract increases lung cell ceramide
production and secretion
The deleterious effect of cigarette smoking on heart
function is undeniable, but the mechanism communi-
cating the pulmonary insult to the heart is not clear. As
proof of concept that the lung is capable of producing
and secreting ceramides with smoke exposure, we
treated A549 alveolar type 2 cells with cigarette smoke
extract (CSE). Relative to PBS treatment, ceramides
increased over 60% in CSE-treated lung cells, though
this effect was mitigated with myriocin co-treatment
(Figure 2A). Further, CSE treatment elicited an almost
three-fold increase in ceramide secretion into medium
compared with PBS treatment (Figure 2B). We also
observed an upward trend (P = 0.069) in circulatingFigure 4 Myriocin prevents left ventricle ceramide accrual and mitoch
room air (Con) or cigarette smoke (CS) for 1 wk while receiving PBS (vehicl
from left ventricle following treatment period (n = 6). B: Mitochondrial re
(n = 6). *P <0.05 for CS vs all other treatments.ceramides from whole blood following 5 d of sidestream
smoke exposure in adult mice (Figure 2C).Ceramide is necessary for smoke extract-induced altered
cardiomyocyte mitochondrial disruption
To determine the effects of lung cell-secreted ceramides
on heart cell function, we utilized a conditioned medium
in vitro model. Briefly, following incubation with PBS-
or CSE-containing medium, with or without myriocin
co-treatment, the conditioned medium from lung cells
was transferred to H9C2 cardiomyotubes for 12 h.
Following the incubation with conditioned medium, we
determined cardiomyotube ceramide accrual and mito-
chondrial respiration. Ceramides were significantly in-
creased in cardiomyotubes treated with conditioned
medium from CSE-treated lung cells (Figure 3A). How-
ever, when lung cells received treatment with myriocin
in addition to CSE, the conditioned medium had no
effect on heart cell ceramides (Figure 3A). Mitochondrial
respiration in the heart cells followed a similar trend as
ceramides. Namely, respiration in heart cells receiving
CSE conditioned medium was negatively affected, butondrial dysfunction with cigarette smoke. Mice were exposed to
e) or myriocin injections every other day. A: Ceramides were measured
spiration was reduced with CS treatment in vehicle-injected animals
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medium (Figure 3B).
Ceramide inhibition prevents reduced myocardial
mitochondrial respiration with cigarette smoke
To more accurately determine the role of ceramides in
mediating smoke-induced decayed heart mitochondrial
respiration, we exposed animals to CS for 1 wk while re-
ceiving injections of PBS (vehicle) or myriocin every
other day. Left ventricle ceramides increased four
fold with CS compared with room air-exposed mice
(Figure 4A) with vehicle injections, though myriocin pre-
vented this effect. Moreover, respiration was protected
from CS in myriocin-injected animals (Figure 4B).
Given the evidence suggesting the role of diet in
increasing heart complications [25] and ceramide accrual
[26], we provided a high-fat, high-sugar (Western diet;
WD) to animals in conjunction with smoke (or room air)
exposure over the course of an 8-wk study. Similar to be-
fore, animals received vehicle (PBS) or myriocin injections
every other day. In addition to observing a roughly 6-fold
increase in heart ceramides with smoke exposure, we
found an equally great increase in heart ceramides inFigure 5 Western diet exerts a minimal effect on heart ceramides in s
cigarette smoke (CS) for 8 wk while receiving PBS (vehicle) or myriocin inje
or Western diet (WD). A: Ceramides were measured from left ventricle follo
determined from permeabilized left ventricle myocardium (n = 8). *P <0.05
WD + CS vehicle.animals receiving WD diet and smoke (Figure 5A). How-
ever, ceramide inhibition was only partially successful in
the WD+CS group. In general, ceramide accrual was
associated with reduced myocardial mitochondrial res-
piration (Figure 5B).
Discussion
Previous research demonstrated that smoke exposure
contributes to cardiomyopathy [27,28], which can be a
consequence of altered mitochondrial function [21], and
we have recently shown that sidestream smoke alters
mitochondrial function in skeletal muscle [29]. Consid-
ering current worldwide smoking trends [3,4], cardiomy-
opathy and other cardiovascular burdens mediated by
cigarette smoke are likely to increase. To date, the main
instigators thought to mediate the heart-specific effects
of smoking are altered blood lipids and changes in
fibrinogen metabolism, [30,31], though the actual impact
of these mechanisms is unknown [30]. While ceramides
are known to mediate cellular disruption in the lung
with smoking [32], its impact on cardiomyocyte function
with smoking has not been adequately explored. Thus,
the purpose of this project was to determine the role ofmoke-exposed mice. Mice were exposed to room air (Con) or
ctions every other day. Mice also received either a standard diet (SD)
wing treatment period (n = 4). B: Mitochondrial respiration was
for treatment vs. Vehicle SD. #P <0.05 for WD + CS myriocin vs.
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myocyte mitochondrial function. Our major discoveries
were that lung cells secrete ceramide with sidestream
smoke exposure and that ceramide accumulates in heart
tissue and alters mitochondrial function.
To our knowledge, the first study to explore the effects
of ceramide on mitochondrial respiration was published
by the Hoppel laboratory, where they observed a rapid
and robust inhibition of respiration in isolated heart
mitochondria upon ceramide treatment [20], and sub-
sequent work corroborates these findings [33]. We
confirm those observations by Gudz et al. [20] in iso-
lated heart mitochondria and report similar findings in
permeabilized left ventricle. Additionally, we have
previously shown that ceramides substantially inhibit
complex II action and that the general adverse effect of
ceramides on mitochondrial respiration is dependent
on ceramide-induced mitochondrial fission [24]. Simi-
larly, our findings of ceramide accrual in the lung with
smoking corroborate those from other laboratories
[34-36], but while previous work focused on ceramide
generation via sphingomyelinase, our effective use of
myriocin suggests the importance of de novo ceramide
synthesis in sidestream smoke-induced ceramide accu-
mulation. However, while myriocin injections were
sufficient to completely block ceramide accrual with
smoking or diet separately, it was insufficient to pre-
vent an increase in ceramides with combined smoking
and diet. This may be a result of insufficient myriocin
action in the midst of an overpowering stimulus (diet
and smoke combined), or that sphingomyelinase may
be particularly relevant in our combined treatment.
Importantly, we not only find increased ceramide pro-
duction in lung cells with smoke exposure, but also cer-
amide release, providing proof of concept that the lung
may be at least a source of systemic ceramide accrual
with smoke exposure. This is supported by our finding
of an upward trend in circulating ceramides with smoke
exposure. Nonetheless, ongoing experiments are testing
the hypothesis that secreted ceramide by smoke-exposed
pulmonary tissues travel and accumulate in cardiac
muscle. Related to this, our conclusions that ceramide is
the relevant component within the cultured medium
upon transfer of medium from lung cells to cardiomyo-
cytes is based on our use of myriocin. However, due to
the harmful cocktail of molecules within the CSE, it is
possible that a non-ceramide variable exists.
The level of ceramide accumulation we observe in the
heart with smoking is substantial. We have previously
quantified ceramide in various tissues (i.e., skeletal muscle,
liver, brain) with dietary intervention [17,24,37] and rarely
observed greater than a roughly twofold increase in cer-
amides; similar changes have been observed in the heart
[26]. However, cigarette smoking appears to be a morerobust inducer of systemic ceramide accumulation com-
pared with diet. We found a roughly four-fold increase
in heart ceramides after only 1 wk of smoke exposure
(Figure 4) that increased to a six-fold change with an
8-wk exposure (Figure 4A). Interestingly, supplementing
the smoking regimen with a dietary component (Western
diet, Harlan Teklad 45F30S) had no additive effect on
heart ceramides (Figure 5A).
Conclusions
In conjunction with our recent findings of altered skeletal
muscle function with cigarette smoke exposure [29], the
results of these studies implicate ceramide as an important
mediator of myriad systemic metabolic effects. In par-
ticular, we find evidence that ceramides are a mediator
of sidestream smoke-induced altered heart mitochon-
drial function. While interventions to promote smoking
cessation should continue, the increase in worldwide
smoking and cardiovascular complications highlights
the need for immediate therapies. Our findings suggest
that ceramide inhibition may be a novel and potentially
valuable therapeutic modality to protect heart function
for those who are unwilling or unable to vacate smoke
environments.
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